G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors

Toxicon

Volumn 59, Issue 4, 2012, Pages 487-496

  Maïga, Arhamatoulaye ^a   Mourier, Gilles ^a   Quinton, Loïc ^b   Rouget, Céline ^a,c   Gales, Céline ^c,d   Denis, Colette ^c,d   Lluel, Philippe ^c   Sénard, Jean Michel ^c,d   Palea, Stefano ^c   Servent, Denis ^a   Gilles, Nicolas ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d INSERM   (France)

Author keywords

Animal toxins; Benign prostate hypertrophy; Drug development; G protein coupled receptor; Hypotension; In vivo; Screening

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; DA1A PEPTIDE; DA1B PEPTIDE; G PROTEIN COUPLED RECEPTOR; MUSCARINIC RECEPTOR; SNAKE VENOM; TAMSULOSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; BINDING AFFINITY; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DENDROASPIS; DRUG SCREENING; FEMALE; HEART RATE; HYPOTENSION; ILEUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; REVIEW; SEQUENCE HOMOLOGY; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; SNAKE; URETHRA PRESSURE;

ADRENERGIC ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; DRUG DISCOVERY; ELAPID VENOMS; ELAPIDAE; HYPOTENSION; LIGANDS; MALE; MOLECULAR SEQUENCE DATA; POSTOPERATIVE PERIOD; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ALIGNMENT;

ANIMALIA; CROCODYLUS NILOTICUS; DENDROASPIS ANGUSTICEPS;

EID: 84857040368     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.03.009     Document Type: Review

References (47)

1. Acritopoulou-Fourcroy S., Marcais-Collado H. Involvement of alpha-adrenoceptors in myometrial responses in the pro-oestral rat. Br. J. Pharmacol. 1988, 93:185-191.
2. Bardou M., Loustalot C., Cortijo J., Simon B., Naline E., Dumas M., Esteve S., Croci T., Chalon P., Frydman R., Sagot P., Manara L., Morcillo E.J., Advenier C. Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium. Br. J. Pharmacol. 2000, 130:1960-1966.
3. Bradley K.N. Muscarinic toxins from the green mamba. Pharmacol. Ther. 2000, 85:87-109.
4. Bullock T.L., Andriole G.L. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin. Emerg. Drugs 2006, 11:111-123.
5. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
6. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L., Newman A.H., Javitch J.A., Cherezov V., Stevens R.C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
7. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 2002, 1:198-210.
8. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54:323-374.
9. Craig A.G., Norberg T., Griffin D., Hoeger C., Akhtar M., Schmidt K., Low W., Dykert J., Richelson E., Navarro V., Mazella J., Watkins M., Hillyard D., Imperial J., Cruz L.J., Olivera B.M. Contulakin-G, an O-glycosylated invertebrate neurotensin. J. Biol. Chem. 1999, 274:13752-13759.
10. Cruz L.J., de Santos V., Zafaralla G.C., Ramilo C.A., Zeikus R., Gray W.R., Olivera B.M. Invertebrate vasopressin/oxytocin homologs. Characterization of peptides from Conus geographus and Conus straitus venoms. J. Biol. Chem. 1987, 262:15821-15824.
11. Delaflotte S., Auguet M., Chabrier P.E. Pharmacological evidence that different alpha 1 adrenoceptor subtypes mediate contraction in rabbit prostate and hypogastric artery. Acta Physiol. Scand. 1996, 158:241-251.
12. Ducancel F. Endothelin-like peptides. Cell Mol. Life Sci. 2005, 62:2828-2839.
13. Harvey A.L., Kornisiuk E., Bradley K.N., Cervenansky C., Duran R., Adrover M., Sanchez G., Jerusalinsky D. Effects of muscarinic toxins MT1 and MT2 from green mamba on different muscarinic cholinoceptors. Neurochem. Res. 2002, 27:1543-1554.
14. Heading C.E. Conus peptides and neuroprotection. Curr. Opin. Investig. Drugs 2002, 3:915-920.
15. Ibuki R., Haga N., Muramatsu S., Mizumoto A., Itoh Z. Long-term observations of uterine contractions in nonpregnant dogs. Biol. Reprod. 1997, 56:632-639.
16. Jaakola V.P., Ijzerman A.P. The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. Curr. Opin. Struct. Biol. 2010, 20:401-414.
17. Jacoby E., Bouhelal R., Gerspacher M., Seuwen K. The 7 TM G-protein-coupled receptor target family. Chem. Med. Chem. 2006, 1:761-782.
18. Jolkkonen M., Oras A., Toomela T., Karlsson E., Jarv J., Akerman K.E. Kinetic evidence for different mechanisms of interaction of black mamba toxins MT alpha and MT beta with muscarinic receptors. Toxicon 2001, 39:377-382.
19. Joubert F.J. The amino acid sequence of protein CM-3 from Dendroaspis polylepis polylepis (black mamba) venom. Int. J. Biochem. 1985, 17:695-699.
20. King G.F., Gentz M.C., Escoubas P., Nicholson G.M. A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 2008, 52:264-276.
21. Koivula K., Rondinelli S., Nasman J. The three-finger toxin MTalpha is a selective alpha(2B)-adrenoceptor antagonist. Toxicon 2010, 56:440-447.
22. Kojima Y., Sasaki S., Shinoura H., Hayashi Y., Tsujimoto G., Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 2006, 66:761-767.
23. Kroeze W.K., Sheffler D.J., Roth B.L. G-protein-coupled receptors at a glance. J. Cell Sci. 2003, 116:4867-4869.
24. Lewis R.J., Garcia M.L. Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2003, 2:790-802.
25. Ménez A., Gillet D., Grishin E. Toxins: threats and Benefits. Recent Research Developments in Toxins from Bacteria and Other Organisms 2006, 1-33. Research Signpost, Kerala. D. Gillet, L. Johannes (Eds.).
26. Menez A. Functional architectures of animal toxins: a clue to drug design?. Toxicon 1998, 36:1557-1572.
27. Michel M., Insel P. Adrenergic receptor in clinical medecine. The Adrenergic Receptors 2006, vol. 1:129-150. Humana Press, Totowa. P. DM (Ed.).
28. Michel M.C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 2006, 147(Suppl. 2):S88-S119.
29. Nielsen D.B., Dykert J., Rivier J.E., McIntosh J.M. Isolation of Lys-conopressin-G from the venom of the worm-hunting snail, Conus imperialis. Toxicon 1994, 32:845-848.
30. O'Brien D.P., Senagore A., Merlino J., Brady K., Delaney C. Predictors and outcome of readmission after laparoscopic intestinal surgery. World J. Surg. 2007, 31:2430-2435.
31. Olivera B.M., Cruz L.J., de Santos V., LeCheminant G.W., Griffin D., Zeikus R., McIntosh J.M., Galyean R., Varga J., Gray W.R., et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987, 26:2086-2090.
32. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
33. Quinton L., Girard E., Maiga A., Rekik M., Lluel P., Masuyer G., Larregola M., Marquer C., Ciolek J., Magnin T., Wagner R., Molgo J., Thai R., Fruchart-Gaillard C., Mourier G., Chamot-Rooke J., Menez A., Palea S., Servent D., Gilles N. Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor. Br. J. Pharmacol. 2010, 159:316-325.
34. Rajagopalan N., Pung Y.F., Zhu Y.Z., Wong P.T., Kumar P.P., Kini R.M. Beta-cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. Faseb J. 2007, 21:3685-3695.
35. Rouget C., Quinton L., Maiga A., Gales C., Masuyer G., Malosse C., Chamot-Rooke J., Thai R., Mourier G., De Pauw E., Gilles N., Servent D. Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the alpha(2)-adrenoceptors. Br. J. Pharmacol. 2010, 161:1361-1374.
36. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., Brotchie J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 2003, 18:872-883.
37. Schmidtko A., Lotsch J., Freynhagen R., Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375:1569-1577.
38. Selvam e.a. J. Med. Chem. 2010, in revision.
39. Servent D., Fruchart-Gaillard C. Muscarinic toxins: tools for the study of the pharmacological and functional properties of muscarinic receptors. J. Neurochem 2009, 109:1193-1202.
40. Sharpe I.A., Gehrmann J., Loughnan M.L., Thomas L., Adams D.A., Atkins A., Palant E., Craik D.J., Adams D.J., Alewood P.F., Lewis R.J. Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat. Neurosci. 2001, 4:902-907.
41. Sharpe I.A., Thomas L., Loughnan M., Motin L., Palant E., Croker D.E., Alewood D., Chen S., Graham R.M., Alewood P.F., Adams D.J., Lewis R.J. Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J. Biol. Chem. 2003, 278:34451-34457.
42. Terlau H., Olivera B.M. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 2004, 84:41-68.
43. Thompson M.D., Burnham W.M., Cole D.E. The G protein-coupled receptors: pharmacogenetics and disease. Crit. Rev. Clin. Lab. Sci. 2005, 42:311-392.
44. Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E., Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C., Bergmann J.E., Gaitanaris G.A. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. U S A 2003, 100:4903-4908.
45. Verwaerde P., Tran M.A., Montastruc J.L., Senard J.M., Portolan G. Effects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension. Fundam. Clin. Pharmacol. 1997, 11:567-575.
46. Westfall T., Westfall D. Adrenergic agonists and antagonists in the 21st century. The Adrenergic Receptors 2006, vol. 1:237-295. Humana press, Totowa, NJ. P. DM (Ed.).
47. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., Hamel D.J., Kuhn P., Handel T.M., Cherezov V., Stevens R.C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.